化合物 AAK1-IN-4|T61499|TargetMol

價(jià)格	￥17500	￥13800	￥10600
包裝	100mg	50mg	25mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 AAK1-IN-4	英文名稱:AAK1-IN-4
CAS:1815612-79-3	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Shipping with blue ice.
產(chǎn)品類別: 抑制劑
貨號(hào): T61499

Product Introduction

Bioactivity

名稱	AAK1-IN-4
描述	AAK1-IN-4 is a potent and specific inhibitor of adaptor protein-2-associated kinase 1 (AAK1), capable of efficiently penetrating the central nervous system and exhibiting oral bioactivity. It has demonstrated a high degree of selectivity with an AAK1 inhibitory concentration (IC50) of 4.6 nM, a Filt dissociation constant (Ki) of 0.9 nM, and a cellular IC50 of 8.6 nM. AAK1-IN-4 holds promise as a valuable tool in the investigation of neuropathic pain [1].
體外活性	AAK1-IN-4 (compound 43) (0.5 μM, 0-10 min) has good cell potencies of 2.4 in liver microsomes, as well as good metabolic stability (value of 95, 95, 93 for human, rat, and mouse microsomes, respectively) and no issue with CYP inhibitions [1].
體內(nèi)活性	AAK1-IN-4 (3 mg/kg; p.o; single) can significantly reduce tactile allodynia with close to 80% inhibition of the pain response in the rat CCI-induced pain model [1]. AAK1-IN-4 (3 mg/kg; p.o; 0-7.5 hours) has good spinal cord penetration and spinal-cord-to-plasma-concentration ratios of 8.8 [1]. AAK1-IN-4 (1-10 mg/kg; p.o.; 0-24.5 hours) can significantly reduces mechanical allodynia with over 80% peak inhibition of the pain response achieved at an oral dose of 10 mg/kg, and over 60% peak inhibition of the pain response at 3 mg/kg [1]. Animal Model: Male Sprague-Dawley rats (chronic constriction injury, CCI) [1] Dosage: 3 mg/kg Administration: p.o, 0-7.5 hours Result: Significantly reduced tactile allodynia with close to 80% inhibition of the pain response, as well as showed good spinal cord penetration and spinal-cord-to-plasma-concentration ratios of 8.8. Animal Model: Male Sprague-Dawley rats (STZ-induced diabetic peripheral neuropathic pain, DPNP) [1] Dosage: 1-10 mg/kg Administration: p.o., 0-24.5 hours Result: Significantly reduced mechanical allodynia with over 80% peak inhibition of the pain response achieved at an oral dose of 10 mg/kg, and over 60% peak inhibition of the pain response at 3 mg/kg.
存儲(chǔ)條件	Shipping with blue ice.

關(guān)鍵字： AAK1-IN-4|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	589.8595萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營行業(yè)	中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 1年

公司成立：12年
注冊(cè)資本：589.8595萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：抑制劑&激動(dòng)劑，天然產(chǎn)物，重組蛋白，化合物庫，技術(shù)服務(wù)
公司地址：上海市靜安區(qū)江場三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 CM304|T71949|TargetMol

￥13800

化合物 BU-E 75|T23835|TargetMol

￥23500

化合物 Amidochlor|T29981|TargetMol

￥17500